search
Back to results

On-X Heart Valve - 17mm Aortic and 23mm Mitral

Primary Purpose

Heart Valve Disease

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
17mm aortic valve (On-X )
23mm mitral valve (On-X)
Sponsored by
On-X Life Technologies, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Valve Disease focused on measuring heart valve

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients of any age; unless waived by local IRB assent of the patient and in all cases consent of parent or legally authorized representative is required if a patient is under the age of majority and not legally emancipated.
  2. Patients who are sufficiently ill to warrant replacement of their diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups.
  3. Patients who are in sufficient satisfactory condition, based on the physical exam and investigator's experience, to be an average or better operative risk, (i.e., likely to survive one year postoperatively).
  4. Patients who require an isolated aortic valve replacement size 17 mm or isolated mitral valve replacement size 23mm.
  5. Patients who are geographically stable and willing to return to the implanting center for follow-up visits.
  6. Patients or legally authorized representatives who are adequately informed of their participation in the clinical study and what will be required of them in order to comply with the protocol.
  7. Patients requiring concomitant cardiovascular surgery, such as coronary bypass may be included in the study.

Exclusion Criteria:

1. Patients who are pregnant, planning to become pregnant or are lactating. 2 Patients who have a noncardiac progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient.

3 Patients who have a documented history of substance (drug or alcohol) abuse or are prison inmates.

4. Patients with a previous prosthetic valve, where it is not being replaced by a study valve, or patients requiring multiple valve replacement.

5. Patients with active endocarditis or active myocarditis. 6 Patients who require tricuspid or pulmonic valve replacement. 7. Patients who have not agreed to return for the required number of follow-up visits or who are geographically unavailable for follow-up.

8. Patients who cannot be maintained on long-term anticoagulant therapy. 9. Patients with non-cardiac illness resulting in a life expectancy of less than 1-year.

10. Patients previously enrolled and implanted in this trial may not re-enter after withdrawal.

11. Patients already enrolled in another investigational device or drug study (nor can enrolled patients be enrolled in other studies).

12. Patients with acute preoperative neurological deficit, myocardial infarction, or cardiac event who have not returned to baseline for at least 30-days prior to enrollment.

13. Patients with aortic aneurysm or other medical condition that creates a higher than usual risk of surgical complication.

14. Patients who are prisoners or mentally ill, and pediatric patients who are incapable of understanding their assent as judged by the principal investigator.

Sites / Locations

  • Arkansas Children's Hospital
  • Maine Medical Center
  • Children's Heart Center Nevada
  • Cincinnati Children's Medical Center
  • University of Oklahoma/Children's Hospital
  • University of Virginia
  • Mary Bridge Children's - Tacoma General Hospital
  • Mayaguez Medical Center
  • Hospital Clinico Provincial
  • University Hospital Salamanca

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

17mm On-X Aortic Heart Valve

23mm On-X Mitral Heart Valve

Arm Description

Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.

Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve. Enrollment into the 23mm On-X mitral arm has been terminated.

Outcomes

Primary Outcome Measures

Hemodynamics as a measure of performance
Pressure gradient

Secondary Outcome Measures

Valve-related adverse events as a measure of safety
Composite rate of thromboembolism, bleeding, structural dysfunction, endocarditis, non-structural dysfunction

Full Information

First Posted
March 12, 2013
Last Updated
June 16, 2023
Sponsor
On-X Life Technologies, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01812174
Brief Title
On-X Heart Valve - 17mm Aortic and 23mm Mitral
Official Title
On-X Heart Valve - 17mm Aortic and 23mm Mitral
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
November 18, 2011 (Actual)
Primary Completion Date
May 30, 2023 (Actual)
Study Completion Date
May 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
On-X Life Technologies, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study examines the hemodynamic and hemolytic properties of two additional smaller size valves to the On-X line of valves already approved by FDA.
Detailed Description
The purpose of the study is to assess the safety and efficacy of the 17mm On-X Aortic Prosthetic Heart Valve and the 23mm On-X Mitral Prosthetic Heart Valve when used to replace diseased aortic or mitral valves in human subjects. The On-X 17mm aortic valve will be implanted in approximately 20 and at least 15 patients who will be followed for at least 1 year. Patients will be any age and will require this size valve as determined in surgery but will be recruited prior to surgery based on results of preoperative screening tests. Enrollment into the 23mm mitral arm of the study has been terminated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Valve Disease
Keywords
heart valve

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients in one arm are recipients of the 17mm On-X Aortic Valve. Patients in the second arm are recipients of the 23mm On-X Mitral Valve. Since double valve cases are exclusionary, these two arms are mutually exclusive and non-randomized.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
17mm On-X Aortic Heart Valve
Arm Type
Experimental
Arm Description
Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.
Arm Title
23mm On-X Mitral Heart Valve
Arm Type
Experimental
Arm Description
Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve. Enrollment into the 23mm On-X mitral arm has been terminated.
Intervention Type
Device
Intervention Name(s)
17mm aortic valve (On-X )
Other Intervention Name(s)
On-X prosthetic heart valve
Intervention Description
Heart aortic valve replacement surgery: 17mm Aortic
Intervention Type
Device
Intervention Name(s)
23mm mitral valve (On-X)
Other Intervention Name(s)
On-X prosthetic heart valve
Intervention Description
Heart mitral valve replacement surgery: 23mm Mitral
Primary Outcome Measure Information:
Title
Hemodynamics as a measure of performance
Description
Pressure gradient
Time Frame
1-year
Secondary Outcome Measure Information:
Title
Valve-related adverse events as a measure of safety
Description
Composite rate of thromboembolism, bleeding, structural dysfunction, endocarditis, non-structural dysfunction
Time Frame
1-year

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients of any age; unless waived by local IRB assent of the patient and in all cases consent of parent or legally authorized representative is required if a patient is under the age of majority and not legally emancipated. Patients who are sufficiently ill to warrant replacement of their diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups. Patients who are in sufficient satisfactory condition, based on the physical exam and investigator's experience, to be an average or better operative risk, (i.e., likely to survive one year postoperatively). Patients who require an isolated aortic valve replacement size 17 mm or isolated mitral valve replacement size 23mm. Patients who are geographically stable and willing to return to the implanting center for follow-up visits. Patients or legally authorized representatives who are adequately informed of their participation in the clinical study and what will be required of them in order to comply with the protocol. Patients requiring concomitant cardiovascular surgery, such as coronary bypass may be included in the study. Exclusion Criteria: 1. Patients who are pregnant, planning to become pregnant or are lactating. 2 Patients who have a noncardiac progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient. 3 Patients who have a documented history of substance (drug or alcohol) abuse or are prison inmates. 4. Patients with a previous prosthetic valve, where it is not being replaced by a study valve, or patients requiring multiple valve replacement. 5. Patients with active endocarditis or active myocarditis. 6 Patients who require tricuspid or pulmonic valve replacement. 7. Patients who have not agreed to return for the required number of follow-up visits or who are geographically unavailable for follow-up. 8. Patients who cannot be maintained on long-term anticoagulant therapy. 9. Patients with non-cardiac illness resulting in a life expectancy of less than 1-year. 10. Patients previously enrolled and implanted in this trial may not re-enter after withdrawal. 11. Patients already enrolled in another investigational device or drug study (nor can enrolled patients be enrolled in other studies). 12. Patients with acute preoperative neurological deficit, myocardial infarction, or cardiac event who have not returned to baseline for at least 30-days prior to enrollment. 13. Patients with aortic aneurysm or other medical condition that creates a higher than usual risk of surgical complication. 14. Patients who are prisoners or mentally ill, and pediatric patients who are incapable of understanding their assent as judged by the principal investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sidney Levitsky, MD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Arkansas Children's Hospital
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72202
Country
United States
Facility Name
Maine Medical Center
City
Portland
State/Province
Maine
ZIP/Postal Code
04102
Country
United States
Facility Name
Children's Heart Center Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89109
Country
United States
Facility Name
Cincinnati Children's Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Facility Name
University of Oklahoma/Children's Hospital
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
University of Virginia
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Facility Name
Mary Bridge Children's - Tacoma General Hospital
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98415
Country
United States
Facility Name
Mayaguez Medical Center
City
Mayaguez
ZIP/Postal Code
00681
Country
Puerto Rico
Facility Name
Hospital Clinico Provincial
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
University Hospital Salamanca
City
Salamanca
ZIP/Postal Code
37008
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

On-X Heart Valve - 17mm Aortic and 23mm Mitral

We'll reach out to this number within 24 hrs